- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00429962
Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
April 6, 2009 updated by: University Hospital, Basel, Switzerland
Randomized, Phase IIIb Study Comparing Safety, Tolerability and Efficacy Between Lucentis® Administered in Conjunction With PDT With Visudyne® and Lucentis® in Patients With Subfoveal CNV Secondary to Age-Related Macular Degeneration
This pilot study is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne®) compared to ranibizumab monotherapy for the treatment of subfoveal CNV secondary to AMD
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Intravitreal ranibizumab has shown to increase average vision in patients with subfoveal CNV secondary to AMD.
However, the treatment does not provide benefit to all patients and the treatment regimen requires monthly intravitreal injections.
Ranibizumab is an anti-VEGF-A monoclonal antibody fragment.
Verteporfin photodynamic therapy acts through occluding newly formed vessels.
The combination of these therapies acting through different modes of action bears the potential to provide a more convenient and less frequent therapy while maintaining/improving the increase in vision improvement observed with ranibizumab monotherapy.
The strategic goal is to evaluate whether intravitreal ranibizumab in combination with verteporfin photodynamic therapy is an effective, safe and convenient treatment for patients with subfoveal CNV secondary to AMD and explore potential advantages of such treatment compared to ranibizumab monotherapy
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Basel-Stadt
-
Basel, Basel-Stadt, Switzerland, 4031
- University Eye Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
patients over 50 years, subfoveal CNV of any type secondary to age-related macular degeneration (AMD), no "macula-treatment for the last 30 days (e.g. with PDT, TA, Laser, Macugen®).
- the area of the CNV must occupy at least >50% of the lesion (total lesion size under 5400 microns in greatest linear dimension)
Occult CNV:
- recent disease progression
- bleeding
- VA decreased the last three months >5 letters or 2 or more than two lines (Snellen)
- 10% increase of the lesion size the last three months
- Best corrected visual acuity score between 24-73 letters (20/40 to 20/320) (ETDRS 4 m)
Exclusion Criteria:
- Prior treatment with mit Laser, PDT, Macugen, TA
- Prior treatment with radiatio, vitrectomy, transpupillary thermotherapy
- History of surgical intervention in the study eye within two months preceding day 1
- concurrent use of systemic anti-VEGF agents
- previous treatment with or participation in a clinical trial involving anti-angiogenic drugs (Pegaptanib, ranibizumab, anecortave acetate of corticosteroids).
- Ocular disorders in the study eye that may confound interpretation of the study results, including retinal detachment or macular hole (Stage 3 or 4), active intraocular inflammation (grade trace or above) or persistent macular edema due to uveitis or other inflammatory diseases
- Retinal pigment epithelium tear, vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye
- History of idiopathic or autoimmune-associated uveitis in either eye, active infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye
- Extracapsular extraction of cataract with phacoemulsification within two months preceding day 1, or a history of post-operative complications within the last 12 months preceding day 1 or a history of post-operative complications within the last 12 months preceding day 1 in the study eye (uveitis, cyclitis, iritis etc.)
- Glaucoma with IOP>25 mmHg despite therapy
- Aphakia or absence of the posterior capsule in the study eye
- Spherical equivalent >-8
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
|
intraocular injection photodynamic treatment (LASER) after intravenous injection
Other Names:
|
Active Comparator: B
intravitreal ranibizumab
|
intraocular injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
First injection with PDT
Time Frame: monthly
|
monthly
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Monthly clinical evaluation of safety and necessity of re-intravitreal injection of ranibizumab after three initial injections
Time Frame: monthly
|
monthly
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Ulrike Schneider, MD, University Eye Clinic Basel
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2006
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
January 31, 2007
First Submitted That Met QC Criteria
January 31, 2007
First Posted (Estimate)
February 1, 2007
Study Record Updates
Last Update Posted (Estimate)
April 7, 2009
Last Update Submitted That Met QC Criteria
April 6, 2009
Last Verified
April 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Uveal Diseases
- Choroid Diseases
- Metaplasia
- Macular Degeneration
- Choroidal Neovascularization
- Neovascularization, Pathologic
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- 081-PRC-2006-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on intravitreal ranibizumab & photodynamic therapy
-
University Hospital Inselspital, BerneNovartisCompletedAge Related Macular DegenerationSwitzerland
-
Asociación para Evitar la Ceguera en MéxicoCentro Medico IssemymUnknownSubfoveal Choroidal NeovascularizationMexico
-
Instituto Universitario de Oftalmobiología Aplicada...Fondo de Investigacion SanitariaCompletedChoroidal Neovascularization | MyopiaSpain
-
University of Campania "Luigi Vanvitelli"Completed
-
David M. Brown, M.D.Novartis PharmaceuticalsTerminatedAge-Related Macular DegenerationUnited States
-
Beijing HospitalCompletedDiabetic Macular EdemaChina
-
Ural State Medical UniversityUral Institute of Cardiology; De Haar Research FoundationTerminatedCoronary Artery Disease | Cerebrovascular Disorders | Age-related Macular DegenerationNetherlands, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedMacular Edema | Retinal Vein OcclusionUnited States
-
Illinois Retina AssociatesNovartis PharmaceuticalsCompletedAge-Related Macular DegenerationUnited States
-
Centre Hospitalier Universitaire de NiceWithdrawnDystrophic Epidermolysis BullosaFrance